

STN Search

FILE 'HOME' ENTERED AT 15:28:37 ON 09 DEC 2003

L1 18623 INFLUENZA (S) VIRUS (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN)
L2 21867 INFLUENZA (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN) AND INFLUENZA (S) VIRUS
L3 97 L2 AND (HEAT (S) INACTIVAT##### OR HEAT-INACTIVAT####) (S) (VIRUS OR IMMUNOGEN OR INFLUENZA)
L6 648 L2 AND (ORAL## OR PILL OR TABLET OR CAPSULE) (P) (VACCINE OR VIRUS OR COMPOSTION OR FORMULAT####)

(FILE 'HOME' ENTERED AT 15:28:37 ON 09 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 15:30:07 ON 09 DEC 2003

L1 18623 S INFLUENZA (S) VIRUS (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN
L2 21867 S INFLUENZA (P) (VACCINE OR IMMUNOGEN##### OR ANTIGEN) AND INFL
L3 97 S L2 AND (HEAT (S) INACTIVAT##### OR HEAT-INACTIVAT####) (S) (
L4 44 DUP REM L3 (53 DUPLICATES REMOVED)
L5 30 S L4 NOT PY>2000
L6 648 S L2 AND (ORAL## OR PILL OR TABLET OR CAPSULE) (P) (VACCINE OR
L7 10 S L6 AND L3
L8 28 S L5 NOT L7

L7 ANSWER 1 OF 10 MEDLINE on STN
 AN 97347317 MEDLINE
 DN 97347317 PubMed ID: 9203656
 TI Adjuvant activity of the **heat-labile** enterotoxin from enterotoxigenic *Escherichia coli* for **oral** administration of **inactivated influenza virus vaccine**.
 AU Katz J M; Lu X; Young S A; Galphin J C
 CS Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
 SO JOURNAL OF INFECTIOUS DISEASES, (1997 Feb) 175 (2) 352-63.
 Journal code: 0413675. ISSN: 0022-1899.
 CY United States
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199707
 ED Entered STN: 19970724
 Last Updated on STN: 19970724
 Entered Medline: 19970716
 AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile** enterotoxin (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:66290 CAPLUS
 DN 137:167825
 TI Mutant *Escherichia coli* **heat-labile** enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to **orally** administered **inactivated influenza vaccine**.
 AU Lu, Xiuhua; Clements, J. D.; Katz, Jacqueline M.
 CS Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA
 SO Vaccine (2002), 20(7-8), 1019-1029
 CODEN: VACCDE; ISSN: 0264-410X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB **Influenza vaccines** capable of inducing both systemic and mucosal antibody responses are highly desirable. Optimal induction of

mucosal IgA is accomplished by mucosal delivery of **vaccine**. Mucosal adjuvants may improve the **immunogenicity** and efficacy of **vaccines** delivered by this route. Here, we compare the adjuvant activities of a mutant of **heat-labile enterotoxin** from *Escherichia coli* [LT(R192G)] with those of the wildtype LT (wtLT) for **oral vaccination with inactivated influenza vaccine** in BALB/c mice. Compared with administration of **oral influenza vaccine** alone, co-administration of **vaccine** with LT(R192G) provided enhanced protection from infection in the upper and lower respiratory tract equiv. to and at similar doses as that obtained with wtLT. Likewise, LT(R192G) augmented **virus-specific** IgG and IgA responses in serum, lung and nasal washes and the nos. of **virus-specific** antibody-forming cells in spleen, lung and Peyer's patches in a manner comparable to wtLT. **Virus-specific** splenic CD4+ cells from mice administered **oral vaccine** with either adjuvant produced a mixed Th1- and Th2-type cytokine response pattern. Taken together, these results indicate that LT(R192G), like wtLT, is a potent adjuvant for **oral vaccination of mice with influenza vaccine**.

RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:125169 CAPLUS

DN 126:180877

TI Adjuvant activity of the **heat-labile enterotoxin** from enterotoxigenic *Escherichia coli* for **oral** administration of **inactivated influenza virus vaccine**

AU Katz, Jacqueline M.; Lu, Xiuhua; Young, Sarah A.; Galphin, Judith C.

CS Influenza Branch, Natl. Cent. Infectious Diseases, Atlanta, GA, USA

SO Journal of Infectious Diseases (1997), 175(2), 352-363

 CODEN: JIDIAQ; ISSN: 0022-1899

PB University of Chicago Press

DT Journal

LA English

AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are need to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery or **inactivated influenza vaccine** with the **heat-labile enterotoxin** (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice crit. for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus-specific** proliferative T cells, interleukin-2 prodn., and major histocompatibility complex class-I-restricted cytotoxic T cells.

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1985:452369 CAPLUS

DN 103:52369

TI Use of gamma-inactivated **vaccines** for immunization against **influenza** in animal experiments

AU Bergmann, K. C.; Noack, K.; Tischner, H.; Pohl, W. D.; Nordheim, W.;
 CS Braeuniger, S.; Petzold, G.; Ngyen, H.
 SO Res. Inst. Lung Dis. Tuberc., Berlin, Ger. Dem. Rep.
 ZfI-Mitteilungen (1984), 98, 673-8
 CODEN: ZIMIDC; ISSN: 0323-8776
 DT Journal
 LA English
 AB 60Co-.gamma.-**inactivated influenza** (A/PR/8/34)
vaccines were compared with live and conventionally **heat**
-inactivated vaccines administered by the **oral**
 or parenteral route to NMRI-mice. As compared to the parenteral group,
oral immunization with inactivated **vaccines** leads to
 higher secretory antibody response in the lung. The antibody response
 correlates with protection against lethal **virus** challenge by
 aerosol characterized by a low cell yield and **virus** titer in the
 lung and high survival rate. In monkeys (macacus rhesus) the **oral**
 uptake of a .gamma.-inactivated **influenza vaccine**
 leads also to the occurrence of specific antibodies in nasal secretions
 and saliva and was well tolerated. Thus, inactivation by irradiation can be
 used for easy and probably inexpensive production of **oral**
influenza vaccines.

L7 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2002:343979 BIOSIS
 DN PREV200200343979
 TI Effect of pre-existing anti-LT (heat-labile enterotoxin of Escherichia
 coli) immunity on the efficacy of **oral influenza**
vaccine.

AU Lu, Xiuhua [Reprint author]; Katz, Jacqueline M. [Reprint author]
 CS Influenza Branch, CDC, 1600 Clifton Rd, Atlanta, GA, 30333, USA
 SO FASEB Journal, (March 20, 2002) Vol. 16, No. 4, pp. A680. print.
 Meeting Info.: Annual Meeting of the Professional Research Scientists on
 Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 19 Jun 2002
 Last Updated on STN: 19 Jun 2002
 AB Previously, we have shown that **heat**-labile enterotoxin (LT) from
 E. coli and its low-toxicity mutant (LTR192G) are powerful adjuvants for
 the mucosal delivery of **inactivated influenza**
vaccine to BALB/c mice. However, these adjuvants are also potent
 mucosal **immunogens**. Thus for **vaccines** such as the
influenza vaccine, which may be administered annually to
 individuals, a key question is whether pre-existing immunity to LT would
 result in reduced adjuvant activity and hence, **vaccine** efficacy.
 To address this question, we compared the levels of **virus**
 -specific antibody production, cytokine production, and protective
 efficacy induced by **oral influenza vaccine**
 administered with LT adjuvant to mice that were or were not previously
 immunized with LT. We demonstrated that while preexisting immunity to LT
 reduced the subsequent serum and local **influenza virus**
 -specific antibody responses and cytokine production, the protective
 effect of the **influenza vaccine** was not impaired.
 Further evaluation of the safety and adjuvant activity of low toxicity
 mutants of LT will determine the ultimate utility of such adjuvants in
 humans.

L7 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1997:107155 BIOSIS

DN PREV199799406358
 TI Adjuvant activity of the **heat**-labile enterotoxin from enterotoxigenic Escherichia coli for **oral** administration of **inactivated influenza virus vaccine**.
 AU Katz, Jacqueline M. [Reprint author]; Lu, Xiuhua; Young, Sarah A.; Galphin, Judith C.
 CS Influenza Branch, Mailstop G16, Div. Viral and Rickettsial Dis., Cent. Dis. Control Prev., 1600 Clifton Rd., Atlanta, GA 30333, USA
 SO Journal of Infectious Diseases, (1997) Vol. 175, No. 2, pp. 352-363. CODEN: JIDIAQ. ISSN: 0022-1899.
 DT Article
 LA English
 ED Entered STN: 10 Mar 1997
 Last Updated on STN: 10 Mar 1997
 AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat**-labile enterotoxin (LT) from enterotoxigenic Escherichia coli elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 7 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
 AN 2002060517 EMBASE
 TI Mutant Escherichia coli **heat**-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to **orally** administered **inactivated influenza vaccine**.
 AU Lu X.; Clements J.D.; Katz J.M.
 CS J.M. Katz, Div. of Viral/Rickettsial Diseases, Natl. Center for Infectious Diseases, Ctr. for Disease Control/Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. jkatz@cdc.gov
 SO Vaccine, (15 Jan 2002) 20/7-8 (1019-1029).
 Refs: 73
 ISSN: 0264-410X CODEN: VACCDE
 PUI S 0264-410X(01)00452-2
 CY United Kingdom
 DT Journal; Article
 FS 004 Microbiology
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA English
 SL English
 AB **Influenza vaccines** capable of inducing both systemic and mucosal antibody responses are highly desirable. Optimal induction of mucosal IgA is accomplished by mucosal delivery of **vaccine**.

Mucosal adjuvants may improve the **immunogenicity** and efficacy of **vaccines** delivered by this route. Here, we compare the adjuvant activities of a mutant of **heat-labile enterotoxin** from *Escherichia coli* [LT(R192G)] with those of the wildtype LT (wtLT) for **oral** vaccination with **inactivated influenza vaccine** in BALB/c mice. Compared with administration of **oral influenza vaccine** alone, co-administration of **vaccine** with LT(R192G) provided enhanced protection from infection in the upper and lower respiratory tract equivalent to and at similar doses as that obtained with wtLT. Likewise, LT(R192G) augmented **virus**-specific IgG and IgA responses in serum, lung and nasal washes and the numbers of **virus**-specific antibody-forming cells in spleen, lung and Peyer's patches in a manner comparable to wtLT. **Virus**-specific splenic CD4(+) cells from mice administered **oral vaccine** with either adjuvant produced a mixed Th1- and Th2-type cytokine response pattern. Taken together, these results indicate that LT(R192G), like wtLT, is a potent adjuvant for **oral** vaccination of mice with **influenza vaccine**.

L7 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 97036029 EMBASE
DN 1997036029
TI Adjuvant activity of the **heat-labile enterotoxin** from enterotoxigenic *Escherichia coli* for **oral** administration of **inactivated influenza virus vaccine**.
AU Katz J.M.; Lu X.; Young S.A.; Galphin J.C.
CS Dr. J.M. Katz, Influenza Branch, Div. of Viral/Rickettsial Diseases, Ctrs. for Disease Control/Prevention, 1600 Clifton Rd., Atlanta, GA 30333, United States
SO Journal of Infectious Diseases, (1997) 175/2 (352-363).
Refs: 42
ISSN: 0022-1899 CODEN: JIDIAQ
CY United States
DT Journal; Article
FS 004 Microbiology
037 Drug Literature Index
LA English
SL English
AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection. This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile enterotoxin** (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection. Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone. Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT. The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**. Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L7 ANSWER 9 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 AN 2002:176290 SCISEARCH
 GA The Genuine Article (R) Number: 521TV
 TI Mutant Escherichia coli **heat-labile enterotoxin [LT(R192G)]**
 enhances protective humoral and cellular immune responses to
orally administered inactivated influenza
vaccine
 AU Lu X H; Clements J D; Katz J M (Reprint)
 CS CDCP, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Influenza Branch,
 1600 Clifton Rd, Atlanta, GA 30333 USA (Reprint); CDCP, Natl Ctr Infect
 Dis, Div Viral & Rickettsial Dis, Influenza Branch, Atlanta, GA 30333 USA;
 Tulane Univ, Med Ctr, Dept Microbiol & Immunol, New Orleans, LA 70112 USA
 CYA USA
 SO VACCINE, (15 JAN 2002) Vol. 20, No. 7-8, pp. 1019-1029.
 Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
 OXFORD OX5 1GB, OXON, ENGLAND.
 ISSN: 0264-410X.
 DT Article; Journal
 LA English
 REC Reference Count: 73
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
 AB **Influenza vaccines** capable of inducing both
 systemic and mucosal antibody responses are highly desirable. Optimal
 induction of mucosal IgA is accomplished by mucosal delivery of
vaccine, Mucosal adjuvants may improve the **immunogenicity**
 and efficacy of **vaccines** delivered by this route. Here, we
 compare the adjuvant activities of a mutant of **heat-labile**
 enterotoxin from Escherichia coli [LT(R192G)] with those of the wildtype
 LT (wtLT) for **oral** vaccination with **inactivated**
influenza vaccine in BALB/c mice. Compared with
 administration of **oral influenza vaccine**
 alone, co-administration of **vaccine** with LT(R192G) provided
 enhanced protection from infection in the upper and lower respiratory
 tract equivalent to and at similar doses as that obtained with wtLT.
 Likewise, LT(R192G) augmented **virus**-specific I-G and I-A
 responses in serum, lung and nasal washes and the numbers of **virus**
 -specific antibody-forming cells in spleen, lung and Peyer's patches in a
 manner comparable to wtLT. **Virus**-specific splenic CD4(+) cells
 from mice administered **oral vaccine** with either
 adjuvant produced a mixed Th1 - and Th2-type cytokine response pattern.
 Taken together, these results indicate that LT(R192G), like wtLT, is a
 potent adjuvant for **oral** vaccination of mice with
influenza vaccine. Published by Elsevier Science Ltd.

L7 ANSWER 10 OF 10 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 AN 97:118413 SCISEARCH
 GA The Genuine Article (R) Number: WF063
 TI Adjuvant activity of the **heat-labile enterotoxin** from
 enterotoxigenic Escherichia coli for **oral** administration of
inactivated influenza virus vaccine
 AU Katz J M (Reprint); Lu X H; Young S A; Galphin J C
 CS CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL
 DIS, INFLUENZA BRANCH, ATLANTA, GA 30333 (Reprint); ST JUDE CHILDRENS
 HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38105
 CYA USA
 SO JOURNAL OF INFECTIOUS DISEASES, (FEB 1997) Vol. 175, No. 2, pp. 352-363.
 Publisher: UNIV CHICAGO PRESS, 5720 S WOODLAWN AVE, CHICAGO, IL 60637.
 ISSN: 0022-1899.
 DT Article; Journal
 FS LIFE; CLIN
 LA English

REC Reference Count: 42

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Alternative strategies for vaccination against **influenza** that elicit both systemic antibody and mucosal IgA responses are needed to improve the efficacy in protection against infection, This study demonstrated that **oral** delivery of **inactivated influenza vaccine** with the **heat-labile** enterotoxin (LT) from enterotoxigenic *Escherichia coli* elicited the spectrum of humoral and cell-mediated responses in BALB/c mice critical for the protection and recovery from **influenza virus** infection, Coadministration of LT with **oral influenza vaccine** increased antiviral serum IgG and mucosal IgA responses compared with administration of **oral influenza vaccine** alone, Serum hemagglutination-inhibition and neutralizing antibodies were also augmented by LT, The adjuvant potentiated protection from infection with **influenza A H3N2 viruses** in mouse lower and upper respiratory tracts, enabling the use of lower doses of **oral vaccine**, Coadministration of LT with **oral inactivated influenza vaccine** induced **influenza virus**-specific proliferative T cells, interleukin-2 production, and major histocompatibility complex class I-restricted cytotoxic T cells.

L8 ANSWER 1 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2000507325 MEDLINE
DOCUMENT NUMBER: 20507670 PubMed ID: 11053627
TITLE: Comparison of in vitro immunostimulatory potential of live
and inactivated **influenza viruses**.
AUTHOR: Blazevic V; Trubey C M; Shearer G M
CORPORATE SOURCE: Experimental Immunology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland 20892,
USA.
CONTRACT NUMBER: NO1-CO-56000 (NCI)
SOURCE: HUMAN IMMUNOLOGY, (2000 Sep) 61 (9) 845-9.
Journal code: 8010936. ISSN: 0198-8859.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200011
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001128

L8 ANSWER 2 OF 28 MEDLINE on STN
ACCESSION NUMBER: 1999346227 MEDLINE
DOCUMENT NUMBER: 99346227 PubMed ID: 10417205
TITLE: Intranasal immunization of mice with **influenza**
vaccine in combination with the adjuvant LT-R72
induces potent mucosal and serum immunity which is stronger
than that with traditional intramuscular immunization.
AUTHOR: Barackman J D; Ott G; O'Hagan D T
CORPORATE SOURCE: Chiron Corporation, Emeryville, California, USA..
john.barackman@cc.chiron.com
SOURCE: INFECTION AND IMMUNITY, (1999 Aug) 67 (8) 4276-9.
Journal code: 0246127. ISSN: 0019-9567.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199908
ENTRY DATE: Entered STN: 19990820
Last Updated on STN: 19990820
Entered Medline: 19990812

L8 ANSWER 3 OF 28 MEDLINE on STN
ACCESSION NUMBER: 96096440 MEDLINE
DOCUMENT NUMBER: 96096440 PubMed ID: 7500011
TITLE: Inactivated **influenza virus**, when
presented on dendritic cells, elicits human CD8+ cytolytic
T cell responses.
AUTHOR: Bender A; Bui L K; Feldman M A; Larsson M; Bhardwaj N
CORPORATE SOURCE: Rockefeller University, Laboratory of Cellular Physiology
and Immunology, New York 10021, USA.
CONTRACT NUMBER: AR-39552 (NIAMS)
AR-42557 (NIAMS)
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, (1995 Dec 1) 182 (6)
1663-71.
Journal code: 2985109R. ISSN: 0022-1007.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS

ENTRY MONTH: 199601
ENTRY DATE: Entered STN: 19960217
Last Updated on STN: 19960217
Entered Medline: 19960117

L8 ANSWER 4 OF 28 MEDLINE on STN
ACCESSION NUMBER: 95091056 MEDLINE
DOCUMENT NUMBER: 95091056 PubMed ID: 7998417
TITLE: Escherichia coli heat-labile enterotoxin B subunits
supplemented with a trace amount of the holotoxin as an
adjuvant for nasal **influenza vaccine**.
AUTHOR: Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K;
Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T; +
CORPORATE SOURCE: Department of Pathology, National Institute of Health,
Tokyo, Japan.
SOURCE: VACCINE, (1994 Sep) 12 (12) 1083-9.
Journal code: 8406899. ISSN: 0264-410X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199501
ENTRY DATE: Entered STN: 19950126
Last Updated on STN: 19950126
Entered Medline: 19950119

L8 ANSWER 5 OF 28 MEDLINE on STN
ACCESSION NUMBER: 94295246 MEDLINE
DOCUMENT NUMBER: 94295246 PubMed ID: 8023550
TITLE: Synergistic action of cholera toxin B subunit (and
Escherichia coli heat-labile toxin B subunit) and a trace
amount of cholera whole toxin as an adjuvant for nasal
influenza vaccine.
AUTHOR: Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K;
Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H; +
CORPORATE SOURCE: Department of Pathology, National Institute of Health,
Tokyo, Japan.
SOURCE: VACCINE, (1994 Apr) 12 (5) 419-26.
Journal code: 8406899. ISSN: 0264-410X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199408
ENTRY DATE: Entered STN: 19940815
Last Updated on STN: 19940815
Entered Medline: 19940804

L8 ANSWER 6 OF 28 MEDLINE on STN
ACCESSION NUMBER: 93372364 MEDLINE
DOCUMENT NUMBER: 93372364 PubMed ID: 8364212
TITLE: Neutrophils do not bind to or phagocytize human immune
complexes formed with **influenza virus**.
AUTHOR: Ratcliffe D R; Michl J; Cramer E B
CORPORATE SOURCE: Department of Anatomy, State University of New York Health
Science Center, Brooklyn 11203.
CONTRACT NUMBER: AI-16480 (NIAID)
SOURCE: BLOOD, (1993 Sep 1) 82 (5) 1639-46.
Journal code: 7603509. ISSN: 0006-4971.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199310
ENTRY DATE: Entered STN: 19931022
Last Updated on STN: 19931022
Entered Medline: 19931005

L8 ANSWER 7 OF 28 MEDLINE on STN
ACCESSION NUMBER: 88117435 MEDLINE
DOCUMENT NUMBER: 88117435 PubMed ID: 2828525
TITLE: Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.
AUTHOR: Lelie P N; Reesink H W; Lucas C J
CORPORATE SOURCE: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam.
SOURCE: JOURNAL OF MEDICAL VIROLOGY, (1987 Nov) 23 (3) 297-301.
Journal code: 7705876. ISSN: 0146-6615.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 198803
ENTRY DATE: Entered STN: 19900308
Last Updated on STN: 19900308
Entered Medline: 19880315

L8 ANSWER 8 OF 28 MEDLINE on STN
ACCESSION NUMBER: 86046496 MEDLINE
DOCUMENT NUMBER: 86046496 PubMed ID: 3877382
TITLE: Cell-mediated lysis of **heat-inactivated influenza virus**-coated murine targets.
AUTHOR: Hosaka Y; Sasao F; Ohara R
SOURCE: VACCINE, (1985 Sep) 3 (3 Suppl) 245-51.
Journal code: 8406899. ISSN: 0264-410X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198512
ENTRY DATE: Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19851213

L8 ANSWER 9 OF 28 MEDLINE on STN
ACCESSION NUMBER: 84060244 MEDLINE
DOCUMENT NUMBER: 84060244 PubMed ID: 6605933
TITLE: Persistence of **influenza** as an **immunogen** in pulmonary **antigen**-presenting cells.
AUTHOR: Lipscomb M F; Yeakel-Houlihan D; Lyons C R; Gleason R R; Stein-Streilein J
CONTRACT NUMBER: HL 23870 (NHLBI)
SOURCE: INFECTION AND IMMUNITY, (1983 Dec) 42 (3) 965-72.
Journal code: 0246127. ISSN: 0019-9567.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198401
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19970203
Entered Medline: 19840107

L8 ANSWER 10 OF 28 MEDLINE on STN
 ACCESSION NUMBER: 76181590 MEDLINE
 DOCUMENT NUMBER: 76181590 PubMed ID: 4969
 TITLE: Experiments on the role of virus infections in the pathogenesis of bronchial asthma. The role of innate or acquired insufficiency or ergotropic adaptation in the mechanism of genesis of bronchial asthma.
 AUTHOR: Filipp G
 SOURCE: ALLERGOLOGIA ET IMMUNOPATHOLOGIA, (1976 Jan-Feb) 4 (1) 15-28.
 Journal code: 0370073. ISSN: 0301-0546.
 PUB. COUNTRY: Spain
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 197607
 ENTRY DATE: Entered STN: 19900313
 Last Updated on STN: 19980206
 Entered Medline: 19760706

L8 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2000:287404 CAPLUS
 DOCUMENT NUMBER: 133:295055
 TITLE: Safety and **immunogenicity** of intranasally administered **inactivated** trivalent virosome-formulated **influenza vaccine** containing Escherichia coli **heat-labile** toxin as a mucosal adjuvant
 AUTHOR(S): Gluck, Reinhard; Mischler, Robert; Durrer, Peter; Furer, Emil; Lang, Alois B.; Herzog, Christian; Cryz, Stanley J., Jr.
 CORPORATE SOURCE: Swiss Serum and Vaccine Institute Berne, Bern, 3018, Switz.
 SOURCE: Journal of Infectious Diseases (2000), 181(3), 1129-1132
 CODEN: JIDIAQ; ISSN: 0022-1899
 PUBLISHER: University of Chicago Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1993:567717 CAPLUS
 DOCUMENT NUMBER: 119:167717
 TITLE: Hypericin treatment of vaccine agents for improved immunogenicity
 INVENTOR(S): Meruelo, Daniel; Lavie, Gad
 PATENT ASSIGNEE(S): New York University, USA
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9314197	A1	19930722	WO 1993-US364	19930119
W: AU, CA, JP				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AU 9334745 A1 19930803 AU 1993-34745 19930119
 PRIORITY APPLN. INFO.: US 1992-821945 19920116
 WO 1993-US364 19930119

L8 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1986:107771 CAPLUS
 DOCUMENT NUMBER: 104:107771
 TITLE: Sensitive method for rapid detection of influenza A
 antibodies in human serum
 INVENTOR(S): Wruck, Klaus
 PATENT ASSIGNEE(S): Fed. Rep. Ger.
 SOURCE: Ger. Offen., 11 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3426010	A1	19860116	DE 1984-3426010	19840714
PRIORITY APPLN. INFO.:			DE 1984-3426010	19840714

L8 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1983:196233 CAPLUS
 DOCUMENT NUMBER: 98:196233
 TITLE: Effect of **influenza A virus** on
 leukocyte histamine release
 AUTHOR(S): Busse, William W.; Swenson, Cheri A.; Borden, Ernest
 C.; Treuhaft, Mary W.; Dick, Elliot C.
 CORPORATE SOURCE: Dep. Med. Hum. Oncol., Univ. Wisconsin, Madison, WI,
 USA
 SOURCE: Journal of Allergy and Clinical Immunology (1983),
 71(4), 382-8
 CODEN: JACIBY; ISSN: 0091-6749
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L8 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1962:406965 CAPLUS
 DOCUMENT NUMBER: 57:6965
 ORIGINAL REFERENCE NO.: 57:1448i,1449a-b
 TITLE: Lowered resistance to **influenza** infection of
 mice following immunization with mercurial-inactivate
influenza virus
 AUTHOR(S): Ogasawara, K.; Aida, M.; Nagata, I.
 CORPORATE SOURCE: Univ. Nagoya, Japan
 SOURCE: Journal of Immunology (1961), 86, 599-605
 CODEN: JOIMA3; ISSN: 0022-1767
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

L8 ANSWER 16 OF 28 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 ACCESSION NUMBER: 2001:2710 BIOSIS
 DOCUMENT NUMBER: PREV200100002710
 TITLE: Humoral and mucosal immune response in young healthy adults
 of an intranasal Escherichia coli **heat-labile**
 toxin (HLT) adjuvanted compared to a parenteral
inactivated virosome-formulated subunit
influenza vaccine.

AUTHOR(S): Herzog, C. [Reprint author]; Durrer, P. [Reprint author];
 Lang, A. [Reprint author]; Moser, R.; Spyr, C. [Reprint
 author]; Glueck, U.; Glueck, R. [Reprint author]
 CORPORATE SOURCE: Swiss Serum and Vaccine Inst. Berne, Berne, Switzerland
 SOURCE: Abstracts of the Interscience Conference on Antimicrobial
 Agents and Chemotherapy, (2000) Vol. 40, pp. 251. print.
 Meeting Info.: 40th Interscience Conference on
 Antimicrobial Agents and Chemotherapy. Toronto, Ontario,
 Canada. September 17-20, 2000. Interscience Conference on
 Antimicrobial Agents and Chemotherapy; American Society of
 Microbiology.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 Conference; (Meeting Poster)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 21 Dec 2000
 Last Updated on STN: 21 Dec 2000

L8 ANSWER 17 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 1998036607 EMBASE
 TITLE: Conference Science Medal 1997 lecture at British
 Pharmaceutical Conference, Scarborough, United Kingdom,
 September 15-18, 1997: Recent advances in vaccine adjuvants
 for systemic and mucosal administration.
 AUTHOR: O'Hagan D.T.
 CORPORATE SOURCE: D.T. O'Hagan, Chiron Corporation, 4560 Horton Street,
 Emeryville, CA 947608, United States
 SOURCE: Journal of Pharmacy and Pharmacology, (1998) 50/1 (1-10).
 Refs: 57
 ISSN: 0022-3573 CODEN: JPPMAB
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Conference Article
 FILE SEGMENT: 026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English

L8 ANSWER 18 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 96065969 EMBASE
 DOCUMENT NUMBER: 1996065969
 TITLE: Antibody responses in volunteers induced by nasal
influenza vaccine combined with
 Escherichia coli heat labile enterotoxin B subunit
 containing a trace amount of the holotoxin.
 AUTHOR: Hashigucci K.; Ogawa H.; Ishidate T.; Yamashita R.; Kamiya
 H.; Watanabe K.; Hattori N.; Sato T.; Suzuki Y.; Nagamine
 T.; Aizawa C.; Tamura S.-I.; Kurata T.; Oya A.
 CORPORATE SOURCE: E.N.T. Department, Kitasato Institute Hospital, 5-9-1
 Shirokane, Minato-ku, Tokyo 108, Japan
 SOURCE: Vaccine, (1996) 14/2 (113-119).
 ISSN: 0264-410X CODEN: VACCDE
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LANGUAGE: English

SUMMARY LANGUAGE: English

L8 ANSWER 19 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 91203377 EMBASE
DOCUMENT NUMBER: 1991203377
TITLE: Nanoparticle-based drug delivery systems.
AUTHOR: Kreuter J.
CORPORATE SOURCE: Institut fur Pharmazeutische, Technologie, J.W.
Goethe-Universitat, D-6000 Frankfurt, Germany
SOURCE: Journal of Controlled Release, (1991) 16/1-2 (169-176).
ISSN: 0168-3659 CODEN: JCREEC
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 012 Ophthalmology
026 Immunology, Serology and Transplantation
027 Biophysics, Bioengineering and Medical
Instrumentation
047 Virology
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L8 ANSWER 20 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 88120395 EMBASE
DOCUMENT NUMBER: 1988120395
TITLE: Application of the single radial complement fixation test
for serodiagnosis of **influenza**, respiratory
syncytial, mumps, adeno type 3, and herpes simplex type 1
virus infections.
AUTHOR: Sato S.; Ochiai H.; Niwayama S.
CORPORATE SOURCE: Department of Virology, Toyama Medical and Pharmaceutical
University, Toyama, Japan
SOURCE: Journal of Medical Virology, (1988) 24/4 (395-404).
ISSN: 0146-6615 CODEN: JMVIDB
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
047 Virology
LANGUAGE: English
SUMMARY LANGUAGE: English

L8 ANSWER 21 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 88056791 EMBASE
DOCUMENT NUMBER: 1988056791
TITLE: Recognition of noninfectious **influenza**
virus by class I-restricted murine cytotoxic T
lymphocytes.
AUTHOR: Hosaka Y.; Sasao F.; Yamanaka K.; Bennink J.R.; Yewdell
J.W.
CORPORATE SOURCE: Department of Preventive Medicine, Research Institute for
Microbial Diseases, Osaka University, Suita, Osaka 565,
Japan
SOURCE: Journal of Immunology, (1988) 140/2 (606- 610).
ISSN: 0022-1767 CODEN: JOIMA3
COUNTRY: United States
DOCUMENT TYPE: Journal

FILE SEGMENT: 022 Human Genetics
025 Hematology
026 Immunology, Serology and Transplantation
047 Virology

LANGUAGE: English
SUMMARY LANGUAGE: English

L8 ANSWER 22 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 83235382 EMBASE
DOCUMENT NUMBER: 1983235382
TITLE: Single radial complement fixation test using complement film. Assay of the antibody response to strain and type specific **antigens of influenza virus**.

AUTHOR: Sato S.; Motoda S.; Iwase I.; Jo K.
CORPORATE SOURCE: Denka Inst. Biol. Sci., Nihonbashi, Chuo-ku, Tokyo 103, Japan

SOURCE: Journal of Virological Methods, (1983) 7/2 (57-64).
CODEN: JVMEDH

COUNTRY: Netherlands

DOCUMENT TYPE: Journal

FILE SEGMENT: 047 Virology
026 Immunology, Serology and Transplantation

LANGUAGE: English

L8 ANSWER 23 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 79093264 EMBASE
DOCUMENT NUMBER: 1979093264
TITLE: Single-radial-complement-fixation: A new immunodiffusion technique. 2. Assay of the antibody response to the internal **antigens** (MP and NP) of **influenza A virus** in human sera after vaccination and infection.

AUTHOR: Haaheim R.
CORPORATE SOURCE: Vaccine Dept., Nat. Inst. Publ. Hlth, Oslo 1, Norway
SOURCE: Developments in Biological Standardization, (1977) VOL. 39/- (481-484).
CODEN: DVBSA3

COUNTRY: Switzerland

DOCUMENT TYPE: Journal

FILE SEGMENT: 047 Virology

LANGUAGE: English

L8 ANSWER 24 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 78329744 EMBASE
DOCUMENT NUMBER: 1978329744
TITLE: Single-radial-complement-fixation: a new immunodiffusion technique.

AUTHOR: Haaheim L.R.
CORPORATE SOURCE: Vaccine Dept., Nat. Inst. Publ. Hlth, Postuttak-Oslo, Norway

SOURCE: Bulletin of the World Health Organization, (1978) 56/1 (111-116).
CODEN: BWHOA6

COUNTRY: Switzerland

DOCUMENT TYPE: Journal

FILE SEGMENT: 047 Virology
017 Public Health, Social Medicine and Epidemiology

206 Immunology, Serology and Transplantation
LANGUAGE: English
SUMMARY LANGUAGE: French

L8 ANSWER 25 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 77142518 EMBASE
DOCUMENT NUMBER: 1977142518
TITLE: Influence of vaccination with A/PR 8/34 (HO N1)
influenza virus on the oncogenic activity
of polyoma **virus** in newborn Wistar rats.
AUTHOR: Desselberger U.; Drescher J.; Georgii A.; Ostertag H.
CORPORATE SOURCE: Inst. Virol., Med. Hochsch., Hannover, Germany
SOURCE: Cancer Research, (1976) 36/9 (I) (3047-3050).
CODEN: CNREA8
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
016 Cancer
LANGUAGE: English

L8 ANSWER 26 OF 28 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 74197797 EMBASE
DOCUMENT NUMBER: 1974197797
TITLE: **Inactivation** of A2/Hong Kong **influenza**
virus by **heat** and by freeze thawing.
Comparison of untreated and gamma irradiated preparations.
AUTHOR: De Flora S.; Badolati G.
CORPORATE SOURCE: Inst. Hyg., Univ. Genoa, Italy
SOURCE: Bollettino dell'Istituto Sieroterapico Milanese, (1973)
52/4 (293-305).
CODEN: BISMAL
DOCUMENT TYPE: Journal
FILE SEGMENT: 047 Virology
LANGUAGE: English

L8 ANSWER 27 OF 28 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

ACCESSION NUMBER: 1998:524076 SCISEARCH
THE GENUINE ARTICLE: ZX643
TITLE: Vaccination with glutaraldehyde-fixed bovine respiratory
syncytial **virus** (BRSV)-infected cells stimulates
a better immune response in lambs than vaccination with
heat-inactivated cell-free BRSV
AUTHOR: Keles I; Woldehiwet Z (Reprint); Murray R D
CORPORATE SOURCE: UNIV LIVERPOOL, DEPT VET PATHOL, VET FIELD STN, WIRRAL L64
7TE, MERSEYSIDE, ENGLAND (Reprint); UNIV LIVERPOOL, DEPT
VET PATHOL, VET FIELD STN, WIRRAL L64 7TE, MERSEYSIDE,
ENGLAND; UNIV LIVERPOOL, DEPT VET CLIN SCI & ANIM HUSB,
VET FIELD STN, WIRRAL L64 7TE, MERSEYSIDE, ENGLAND
COUNTRY OF AUTHOR: ENGLAND
SOURCE: VACCINE, (JUL 1998) Vol. 16, No. 11-12, pp. 1172-1178.
Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 0264-410X.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE; AGRI
LANGUAGE: English
REFERENCE COUNT: 32

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L8 ANSWER 28 OF 28 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

ACCESSION NUMBER: 91:417619 SCISEARCH
THE GENUINE ARTICLE: FX482
TITLE: NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS
AUTHOR: KREUTER J (Reprint)
CORPORATE SOURCE: JW GOETHE UNIV, INST PHARMAZEUT TECHNOL, W-6000 FRANKFURT,
GERMANY (Reprint)
COUNTRY OF AUTHOR: GERMANY
SOURCE: JOURNAL OF CONTROLLED RELEASE, (1991) Vol. 16, No. 1-2,
pp. 169-176.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: ENGI
LANGUAGE: ENGLISH
REFERENCE COUNT: No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

WEST Search History

DATE: Tuesday, December 09, 2003

Set Name Query side by side

Hit Count Set Name result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L10	L9 and I5	42	L10
L9	influenza same inactivat\$7 and (tablet or oral)	415	L9
L8	denatur\$3 with antigen and vaccine same influenza	86	L8
L7	L6 and @py<2000	26	L7
L6	L5 and L3	111	L6
L5	L2 and (heat-inactivat\$5 or heat adj inactivat\$5 or denatur\$4) with (antigen or protein or HA or haemagglutinin or virus or influenza)	164	L5
L4	L3 and (multivalent or combination or polyvalent or bivalent) same influenza	49	L4
L3	L2 and (multivalent or combination or polyvalent or bivalent) same (vaccine or composition)	185	L3
L2	(heat adj inactivat\$5 or heat-inactivat\$5 or denature) same (virus or influenza or antigen\$5) and (influenza same virus) same (vaccine or antigen or immunogen\$6)	272	L2
L1	(heat adj inactivat\$5 or heat-inactivat\$5) same (influenza same virus and vaccine)	11	L1

END OF SEARCH HISTORY

WEST Search History

DATE: Tuesday, December 09, 2003

Set Name **Query**
side by side

Hit Count **Set Name**
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L3 L2 and oral.clm.

22 L3


L2 L1 and influenza.clm.

116 L2

L1 (vaccine or immunogen\$5) same (oral) and (pill or tablet or capsule)
and influenza adj virus

567 L1

END OF SEARCH HISTORY



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals
Search	PubMed	for	Limits	Preview/Index	History	Clipboard	Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez PubMed

Search	Most Recent Queries	Time	Result
#17	Search (#1 or #12) AND influenza AND inactivat* Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:19:10	<u>35</u>
#18	Search #17 AND (pill or tablet or capsule) Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:19:06	<u>0</u>
#12	Related Articles for PubMed (Select 6480615)	14:17:30	<u>229</u>
#1	Search oral AND vaccine AND influenza Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:11:39	<u>117</u>
#9	Search oral AND vaccine AND influenza AND (pill or tablet) Field: Title/Abstract, Limits: Publication Date to 2000/08/24	14:10:19	<u>1</u>

Related Resources

[Clear History](#)

[Write to the Help Desk](#)
[NCBI | NLM | NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act | Disclaimer](#)

Date: 12/9/03 2:28 PM

2



Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Bio

Search PubMed for [] Preview Go Clear

☒ Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#33	Search #32 not #11 Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:46:02	<u>8</u>
#32	Search heat-inactivat* AND virus AND influenza Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:38:13	<u>36</u>
#31	Search heat-inactivat* AND virus Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:38:01	<u>409</u>
#28	Search heat-inactivat* AND vaccine AND virus Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:37:03	<u>33</u>
#27	Search heat-inactivat* AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:35:55	<u>106</u>
#24	Search heat inactivat* AND influenza AND antigen Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:34:45	<u>4</u>
#23	Search heat inactivat* AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:34:39	<u>2</u>
#22	Search heat-inactivat* AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:34:32	<u>2</u>
#21	Search heat-inactivated AND influenza AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:34:25	<u>1</u>
#20	Search influenza AND heat-inactivated AND vaccine Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:33:44	<u>1</u>
#17	Search influenza AND heat-inactivated AND (oral or mucosal or mucus) Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:32:08	<u>0</u>
#16	Search influenza AND heat-inactivated AND (oral or muc*) Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:31:44	<u>1</u>
#11	Search influenza AND heat-inactivated Field: Title/Abstract, Limits: Publication Date to 2000/08/24	09:27:36	<u>28</u>

#3 Search **influenza AND vaccine AND heat inactivated** 09:22:06 12
Field: **Title/Abstract**, Limits: **Publication Date to 2000/08/24**

#2 Search **influenza AND vaccine AND inactivated** Field: 09:21:56 644
Title/Abstract, Limits: **Publication Date to 2000/08/24**

#1 Search **influenza AND vaccine AND inactivated** 09:21:26 1174

[Clear History](#)

[Write to the Help Desk](#)
[NCBI | NLM | NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act | Disclaimer](#)

Dec 1 2003 07:03:59